Preoperative ferric carboxymaltose to improve anemia before multi-level lumbar fusion in older adults
Official title: The Effectiveness of Preoperative Iron Therapy in Improving Anemia After Multi-level Lumbar Fusion in the Elderly
Run by Xuanwu Hospital, Beijing · NCT07057973 · Data updated 2026-11-12
This trial will test whether giving intravenous ferric carboxymaltose before multi-level lumbar fusion helps older adults with iron-deficiency anemia raise their hemoglobin, reduce complications, and improve recovery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 60 Years to 90 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | July 1, 2026 |
| Study ends | July 1, 2026 |
| Registry record updated | July 10, 2025 |
| Trial ID | NCT07057973 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 65 or older with iron-deficiency anemia (male Hb < 120 g/L, female Hb < 110 g/L) who are scheduled for multi-segment lumbar fusion and can complete required questionnaires and follow-up.
✕Probably not a fit
Patients with decompensated cirrhosis, microcytic anemia, a history of allergy to ferric carboxymaltose or other IV iron, prior spinal tumor/trauma/infection, active inflammatory/immune disease, or age under 65 are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional single-center study at Xuanwu Hospital will give preoperative ferric carboxymaltose to patients aged 65 or older with iron-deficiency anemia scheduled for multi-level lumbar fusion and measure hemoglobin and iron indices on postoperative days 1, 4, and 7. Outcomes include perioperative hemoglobin and iron metabolism markers, 90-day adverse events, and health-related quality of life indicators. Key exclusions include allergy to IV iron, decompensated cirrhosis, microcytic anemia, prior spinal tumor/trauma/infection, inflammatory or immune diseases, and incomplete clinical data. The trial aims to define an optimized preoperative iron supplementation regimen specific to spinal fusion to support faster and safer recovery in the elderly.
Why it matters
Potential benefit: If successful, preoperative ferric carboxymaltose could reduce postoperative anemia and transfusions, lower complication rates, and speed recovery after multi-level lumbar fusion in older adults.
How similar studies have gone: Intravenous iron has been shown to reduce transfusion needs and improve hemoglobin in other surgical populations, but high-quality, spine-specific evidence remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients underwent multi-segment lumbar spine surgery; * IDA patients aged 65 years or older (male: Hb \< 120g/dL; female: Hb \< 110g/dL); * All patients completed the relevant questionnaire survey; Exclusion Criteria: * Age less than 65 years old; * Previous surgery for spinal tumors, trauma or infection; * Inflammatory or immune diseases (such as rheumatoid arthritis or systemic lupus erythematosus), acute kidney injury, progressive cancer and porphyria cutanea tarda); * Non-adjacent segment surgery; * History of allergy to ferric carboxymaltose or any intravenous iron preparations, asthma, atopic dermatitis or allergy; * Decompensated cirrhosis and microcytic anemia; * Incomplete clinical data;
Where it's running
-
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.